Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.67 |
| ▸ | ERBB2 | P04626 | 14/20 | 0.65 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.60 |
| ▸ | JAK3 | P52333 | 1/20 | 0.60 |
| ▸ | CIT | O14578 | 1/20 | 0.58 |
| ▸ | GAK | O14976 | 1/20 | 0.58 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.58 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.58 |
| ▸ | STK10 | O94804 | 1/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | LYN | P07948 | 1/20 | 0.58 |
| ▸ | RET | P07949 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | MET | P08581 | 1/20 | 0.58 |
| ▸ | HCK | P08631 | 1/20 | 0.58 |
| ▸ | SRC | P12931 | 1/20 | 0.58 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.58 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL582305 | 1.00 | EGFR (0.67) | EGFRERBB2ERBB4JAK3CIT | |
| SCHEMBL1418884 | 0.97 | EGFR (0.69) | EGFRERBB2ERBB4JAK3CIT | |
| SCHEMBL1418883 | 0.97 | EGFR (0.69) | EGFRERBB2ERBB4JAK3CIT | |
| SCHEMBL1419032 | 0.95 | EGFR (0.67) | EGFRERBB2ERBB4JAK3CIT | |
| SCHEMBL1419034 | 0.95 | EGFR (0.67) | EGFRERBB2ERBB4JAK3CIT | |
| SCHEMBL6995335 | 0.94 | EGFR (0.66) | EGFRERBB2ERBB4JAK3CIT | |
| SCHEMBL1418615 | 0.93 | EGFR (0.65) | EGFRERBB2ERBB4JAK3CIT | |
| SCHEMBL1418617 | 0.93 | EGFR (0.65) | EGFRERBB2ERBB4JAK3CIT | |
| SCHEMBL1418857 | 0.92 | EGFR (0.63) | EGFRERBB2ERBB4JAK3CIT | |
| SCHEMBL1418856 | 0.92 | EGFR (0.63) | EGFRERBB2ERBB4JAK3CIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2298746-A1 | 4-amino- quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-03-23 | — | — | EP | claimed |
| US-20100310477-A1 | Pharmaceutical compositions based on anticholingerics and additional active ingredients | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG. (DE) | 2010-12-09 | — | — | US | claimed |
| US-20090306072-A1 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PROCESSES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-12-10 | — | — | US | claimed |
| EP-1845992-A1 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CHRONIC RHINOSINUSITIS | Boehringer Ingelheim International GmbH (DE) | 2007-10-24 | — | — | EP | claimed |
| US-20060178364-A1 | Use of EGFR tyrosinkinase inhibitors for treatment of chronic rhinosinusitis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-08-10 | — | — | US | claimed |
| WO-2006082129-A1 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CHRONIC RHINOSINUSITIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-08-10 | — | — | WO | claimed |
| EP-1658860-A1 | Drug compositions comprising anticholinergics and EGFR kinase inhibitors | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2006-05-24 | — | — | EP | claimed |
| EP-1521595-B1 | NOVEL DRUG COMPOSITIONS BASED ON NOVEL ANTICHOLINERGICS AND INHIBITORS OF EGFR-KINASE | BOEHRINGER INGELHEIM PHARMA (DE) | 2006-03-15 | — | — | EP | claimed |
| US-20050165013-A1 | Pharmaceutical compositions containing anticholinergics and EGFR kinase inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-07-28 | — | — | US | claimed |
| US-20050148562-A1 | Pharmaceutical compositions based on anticholinergics and additional active ingredients | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-07-07 | — | — | US | claimed |
| EP-1521595-A1 | NOVEL DRUG COMPOSITIONS BASED ON NOVEL ANTICHOLINERGICS AND INHIBITORS OF EGFR-KINASE | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-04-13 | — | — | EP | claimed |
| EP-1478398-A1 | NEW MEDICINAL COMPOSITIONS ON THE BASIS OF ANTICHOLINERGIC AGENTS AND EGFR KINASE INHIBITORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-11-24 | — | — | EP | claimed |
| EP-1474149-A2 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PROCESSES | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-11-10 | — | — | EP | claimed |
| US-20040048887-A1 | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-11 | — | — | US | claimed |
| WO-2004004775-A1 | NOVEL DRUG COMPOSITIONS BASED ON NOVEL ANTICHOLINERGICS AND INHIBITORS OF EGFR-KINASE | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-15 | — | — | WO | claimed |
| US-20030158196-A1 | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2003-08-21 | — | — | US | claimed |
| WO-2003068264-A1 | NEW MEDICINAL COMPOSITIONS ON THE BASIS OF ANTICHOLINERGIC AGENTS AND EGFR KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG (DE) | 2003-08-21 | — | — | WO | claimed |
| WO-2003066060-A2 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PROCESSES | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG (DE) | 2003-08-14 | — | — | WO | claimed |
| US-20030149062-A1 | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-08-07 | — | — | US | claimed |
| EP-1157011-A1 | 4-AMINO- QUINAZOLINE AND QUINOLINE DERIVATIVES HAVING AN INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES | Boehringer Ingelheim Pharma KG (DE) | 2001-11-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306072-A1 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PROCESSES | ERBB2, EGFR, ERBB4 | EGFR 2/4885ERBB2 1/4885ERBB4 3/4885 |
| US-20050165013-A1 | Pharmaceutical compositions containing anticholinergics and EGFR kinase inhibitors | CHRM3, EGFR, CHRM2 | EGFR 2/4885ERBB2 4/4885ERBB4 15/4885 |
| US-20050148562-A1 | Pharmaceutical compositions based on anticholinergics and additional active ingredients | CHRM3, ADRA2C, PDE3A | EGFR 52/4885ERBB2 96/4885ERBB4 37/4885 |
| US-20100310477-A1 | Pharmaceutical compositions based on anticholingerics and additional active ingredients | PDE4B, CHRM3, ADRA2C | EGFR 43/4885ERBB2 75/4885ERBB4 22/4885 |
| US-20030149062-A1 | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes | ERBB2, EGFR, ERBB4 | EGFR 2/4885ERBB2 1/4885ERBB4 3/4885 |
| US-20040048887-A1 | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors | CHRM3, EGFR, ERBB2 | EGFR 2/4885ERBB2 3/4885ERBB4 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.